News
GNMLF
0.950
NaN%
--
Genomma Lab Faces Challenges with Strategic Optimism
TipRanks · 10/25 00:12
Genomma Lab Faces Challenges Amidst Economic Pressures
TipRanks · 10/24 04:08
Genomma Lab Internacional, S.A.B. de C.V. reports Q3 results
Seeking Alpha · 10/23 14:18
Weekly Report: what happened at GNMLF last week (0908-0912)?
Weekly Report · 09/15 11:20
Weekly Report: what happened at GNMLF last week (0901-0905)?
Weekly Report · 09/08 11:23
Weekly Report: what happened at GNMLF last week (0825-0829)?
Weekly Report · 09/01 11:18
Weekly Report: what happened at GNMLF last week (0818-0822)?
Weekly Report · 08/25 11:29
Weekly Report: what happened at GNMLF last week (0811-0815)?
Weekly Report · 08/18 11:21
Weekly Report: what happened at GNMLF last week (0804-0808)?
Weekly Report · 08/11 11:28
Weekly Report: what happened at GNMLF last week (0728-0801)?
Weekly Report · 08/04 11:31
Weekly Report: what happened at GNMLF last week (0721-0725)?
Weekly Report · 07/28 11:32
Genomma Lab Reports Mixed Q2 2025 Results
TipRanks · 07/25 04:09
Weekly Report: what happened at GNMLF last week (0714-0718)?
Weekly Report · 07/21 11:21
Weekly Report: what happened at GNMLF last week (0707-0711)?
Weekly Report · 07/14 11:31
Weekly Report: what happened at GNMLF last week (0630-0704)?
Weekly Report · 07/07 11:22
Weekly Report: what happened at GNMLF last week (0623-0627)?
Weekly Report · 06/30 11:29
Weekly Report: what happened at GNMLF last week (0616-0620)?
Weekly Report · 06/23 11:21
Weekly Report: what happened at GNMLF last week (0609-0613)?
Weekly Report · 06/16 11:28
Weekly Report: what happened at GNMLF last week (0602-0606)?
Weekly Report · 06/09 11:30
Weekly Report: what happened at GNMLF last week (0526-0530)?
Weekly Report · 06/02 11:39
More
Webull provides a variety of real-time GNMLF stock news. You can receive the latest news about Genoma Lab Intl through multiple platforms. This information may help you make smarter investment decisions.
About GNMLF
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.